相关实验视频
Updated: Jul 20, 2025

04:21
Protein Transfection of Mouse Lung
Published on: May 15, 2013
9.4K
评估新型蛋白质酸酶2A激活剂作为肺的治疗方法
Brian Soto1, Huma Ahmed1, Meshach Pillai1
1Department of Medicine and.
American journal of respiratory cell and molecular biology
|August 1, 2023
概括
一种名为ATUX-792的新药有效地激活蛋白酸酶2A (PP2A),用于治疗吸烟和α-1抗素缺乏引起的肺气,从而保持肺功能.
科学领域:
- 肺部医学 肺部医学
- 药理学 药理学是指药理学的学科.
- 细胞生物学 细胞生物学
背景情况:
- 在肺瘤模型中,蛋白酸酶2A (PP2A) 的活性降低.
- 香烟烟雾和α-1抗素 (AAT) 缺乏会损害肺功能.
- 像DBK-1154这样的现有的PP2A激活剂的稳定性和系统暴露性不佳.
研究的目的:
- 为了比较一种新的,稳定的PP2A激活剂ATUX-792对DBK-1154.4的疗效.
- 在人类支气管上皮细胞和AAT缺乏症的小鼠模型中评估ATUX-792.
- 评估PP2A激活对香烟烟雾引起的肺瘤的影响.
主要方法:
- 人类支气管上皮细胞和Serpina1a-e-knockout小鼠被用ATUX-792或DBK-1154治疗.
- 野生型小鼠经历了长期暴露在香烟烟雾中的复合治疗.
- 分析了肺功能,组织学,细胞活力,PP2A活性和MAP激酶酸化.
主要成果:
- ATUX-792和DBK-1154都激活了PP2A,减少了MAP激酶酸化,并在肺瘤模型中改善了肺功能.
- 治疗ATUX-792减少了气道炎症,空气空间扩大,以及炎症媒介的释放 (CXCL5,CCL17,CXCL16).
- PP2A激活与肺部中性粒细胞透率降低相关.
结论:
- 下一代PP2A激活剂,如ATUX-792,可以恢复压抑的PP2A活性.
- ATUX-792证明了治疗吸烟和AAT缺乏症相关的肺气的治疗潜力.
- 针对PP2A活动是一个有前途的治疗肺瘤治疗策略.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
215
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
215
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
201
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
201
Transducer Mechanism: Enzyme-Linked Receptors
2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.5K
Protein Kinases and Phosphatases
13.2K
Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
13.2K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
205
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
205
The JAK-STAT Signaling Pathway
9.0K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.0K

